Highlights include a link between migraines and T2DM risk in women; fasting-evoked hypoglycemia being overlooked; and how gut microbiome influences the metabolism of diabetes drugs.
Semaglutide (Wegovy) Receives FDA Label Expansion to Include Cardiovascular Risk Reduction
Diabetes Dialogue: Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
Endocrinology Month in Review: February 2024
Diabetes Dialogue: Understanding MARD, Comparing Popular CGM Sensors
SGLT2 Inhibitor Use Lowers Anemia Risk in Patients with Diabetes, CKD
FDA Clears Dexcom Stelo Sensor, First OTC Glucose Sensor in Agency History